Witherspoon R P, Deeg H J, Lum L G, Ochs H D, Hansen J A, Thomas E D, Storb R
Transplantation. 1984 May;37(5):456-61. doi: 10.1097/00007890-198405000-00007.
Immunologic recovery was studied in ten patients with aplastic anemia and 23 patients with hematologic malignancy who received HLA-identical marrow grafts and cyclosporine postgrafting as prophylaxis against graft-versus-host disease. Cyclosporine , 12.5 mg/kg/day, was administered beginning on the day before marrow infusion and continued for 50 days, when it was tapered and discontinued by 6 months postgrafting . Results were compared with data from concurrent and previously described patients receiving methotrexate as prophylaxis for graft-versus-host disease. Patients treated with cyclosporine or methotrexate had lower-than-normal immunologic parameters and were not different from one another 3-5 months postgrafting . By 11 to 18 months after grafting lymphocyte counts had normalized in both groups. Serum IgA levels were low and IgG levels had normalized in methotrexate-treated patients, and IgM was normal in cyclosporine -treated patients. In vivo antibody production to T-dependent antigens and skin test responses to recall antigens continued to be impaired. The response to the neoantigen dinitrochlorobenzene was still impaired in patients treated with cyclosporine and normal in patients given methotrexate. These data suggest that immunologic recovery after marrow transplantation is similar in cyclosporine -treated and methotrexate-treated patients.
对10例再生障碍性贫血患者和23例血液系统恶性肿瘤患者进行了免疫恢复情况的研究，这些患者接受了HLA配型相同的骨髓移植，并在移植后使用环孢素预防移植物抗宿主病。环孢素的剂量为12.5毫克/千克/天，从骨髓输注前一天开始给药，持续50天，然后在移植后6个月逐渐减量并停药。将结果与同期及先前描述的接受甲氨蝶呤预防移植物抗宿主病的患者的数据进行比较。接受环孢素或甲氨蝶呤治疗的患者免疫参数低于正常水平，在移植后3至5个月时两组之间无差异。移植后11至18个月，两组患者的淋巴细胞计数均恢复正常。甲氨蝶呤治疗的患者血清IgA水平较低，IgG水平恢复正常，而环孢素治疗的患者IgM正常。对T细胞依赖性抗原的体内抗体产生以及对回忆抗原的皮肤试验反应仍然受损。接受环孢素治疗的患者对新抗原二硝基氯苯的反应仍然受损，而接受甲氨蝶呤治疗的患者反应正常。这些数据表明，环孢素治疗和甲氨蝶呤治疗的患者在骨髓移植后的免疫恢复情况相似。
